Logo image of CRL

CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis

NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD

165.305  +3.67 (+2.27%)

Fundamental Rating

5

Taking everything into account, CRL scores 5 out of 10 in our fundamental rating. CRL was compared to 57 industry peers in the Life Sciences Tools & Services industry. CRL scores excellent on profitability, but there are concerns on its financial health. CRL has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

CRL had positive earnings in the past year.
CRL had a positive operating cash flow in the past year.
Each year in the past 5 years CRL has been profitable.
Each year in the past 5 years CRL had a positive operating cash flow.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

1.2 Ratios

The Return On Assets of CRL (5.16%) is better than 84.21% of its industry peers.
With an excellent Return On Equity value of 10.92%, CRL belongs to the best of the industry, outperforming 85.96% of the companies in the same industry.
CRL has a better Return On Invested Capital (7.07%) than 82.46% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRL is in line with the industry average of 9.61%.
Industry RankSector Rank
ROA 5.16%
ROE 10.92%
ROIC 7.07%
ROA(3y)5.92%
ROA(5y)5.95%
ROE(3y)14.99%
ROE(5y)15.52%
ROIC(3y)8.07%
ROIC(5y)7.97%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15 20

1.3 Margins

The Profit Margin of CRL (10.17%) is better than 84.21% of its industry peers.
In the last couple of years the Profit Margin of CRL has grown nicely.
CRL's Operating Margin of 15.04% is amongst the best of the industry. CRL outperforms 80.70% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
CRL has a Gross Margin (35.93%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
Industry RankSector Rank
OM 15.04%
PM (TTM) 10.17%
GM 35.93%
OM growth 3Y0.93%
OM growth 5Y0.35%
PM growth 3Y-2.65%
PM growth 5Y2.84%
GM growth 3Y0.29%
GM growth 5Y-0.02%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CRL has been increased compared to 1 year ago.
CRL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CRL has an improved debt to assets ratio.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 2.38 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.38, CRL is in line with its industry, outperforming 56.14% of the companies in the same industry.
CRL has a debt to FCF ratio of 4.16. This is a neutral value as CRL would need 4.16 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.16, CRL is doing good in the industry, outperforming 75.44% of the companies in the same industry.
A Debt/Equity ratio of 0.62 indicates that CRL is somewhat dependend on debt financing.
CRL has a worse Debt to Equity ratio (0.62) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF 4.16
Altman-Z 2.38
ROIC/WACC0.71
WACC9.89%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.3 Liquidity

CRL has a Current Ratio of 1.48. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL's Current ratio of 1.48 is on the low side compared to the rest of the industry. CRL is outperformed by 75.44% of its industry peers.
A Quick Ratio of 1.14 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a Quick ratio of 1.14. This is in the lower half of the industry: CRL underperforms 75.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.14
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

3

3. Growth

3.1 Past

CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.40%.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.09% on average per year.
Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -3.67% in the last year.
The Revenue has been growing by 12.75% on average over the past years. This is quite good.
EPS 1Y (TTM)-9.4%
EPS 3Y9.37%
EPS 5Y12.09%
EPS Q2Q%-4.78%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y12.2%
Revenue growth 5Y12.75%
Sales Q2Q%-1.64%

3.2 Future

Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 6.53% on average per year.
CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.62% yearly.
EPS Next Y-3.27%
EPS Next 2Y-1.41%
EPS Next 3Y2.84%
EPS Next 5Y6.53%
Revenue Next Year-1.71%
Revenue Next 2Y-0.99%
Revenue Next 3Y1.38%
Revenue Next 5Y4.62%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 16.33, CRL is valued correctly.
98.25% of the companies in the same industry are more expensive than CRL, based on the Price/Earnings ratio.
CRL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.28.
With a Price/Forward Earnings ratio of 15.97, CRL is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 94.74% of the companies listed in the same industry.
CRL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 91.29.
Industry RankSector Rank
PE 16.33
Fwd PE 15.97
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

CRL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CRL is cheaper than 100.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CRL is valued cheaper than 96.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.08
EV/EBITDA 10.92
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

CRL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.35
EPS Next 2Y-1.41%
EPS Next 3Y2.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHARLES RIVER LABORATORIES

NYSE:CRL (1/30/2025, 1:54:30 PM)

165.305

+3.67 (+2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)02-12 2025-02-12/amc
Inst Owners102.9%
Inst Owner Change-0.53%
Ins Owners0.81%
Ins Owner Change-4.71%
Market Cap8.45B
Analysts67.2
Price Target220.21 (33.21%)
Short Float %4.46%
Short Ratio3.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.75%
Min EPS beat(2)5.7%
Max EPS beat(2)15.8%
EPS beat(4)4
Avg EPS beat(4)7.88%
Min EPS beat(4)1.38%
Max EPS beat(4)15.8%
EPS beat(8)8
Avg EPS beat(8)7.5%
EPS beat(12)12
Avg EPS beat(12)5.52%
EPS beat(16)16
Avg EPS beat(16)6.57%
Revenue beat(2)1
Avg Revenue beat(2)0.79%
Min Revenue beat(2)-0.86%
Max Revenue beat(2)2.43%
Revenue beat(4)3
Avg Revenue beat(4)0.94%
Min Revenue beat(4)-0.86%
Max Revenue beat(4)2.43%
Revenue beat(8)6
Avg Revenue beat(8)1.69%
Revenue beat(12)8
Avg Revenue beat(12)0.96%
Revenue beat(16)11
Avg Revenue beat(16)1.15%
PT rev (1m)-0.54%
PT rev (3m)2.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.95%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.49%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.92%
Valuation
Industry RankSector Rank
PE 16.33
Fwd PE 15.97
P/S 2.08
P/FCF 15.08
P/OCF 10.62
P/B 2.24
P/tB N/A
EV/EBITDA 10.92
EPS(TTM)10.12
EY6.12%
EPS(NY)10.35
Fwd EY6.26%
FCF(TTM)10.96
FCFY6.63%
OCF(TTM)15.57
OCFY9.42%
SpS79.41
BVpS73.96
TBVpS-2.36
PEG (NY)N/A
PEG (5Y)1.35
Profitability
Industry RankSector Rank
ROA 5.16%
ROE 10.92%
ROCE 8.74%
ROIC 7.07%
ROICexc 7.28%
ROICexgc 17.16%
OM 15.04%
PM (TTM) 10.17%
GM 35.93%
FCFM 13.8%
ROA(3y)5.92%
ROA(5y)5.95%
ROE(3y)14.99%
ROE(5y)15.52%
ROIC(3y)8.07%
ROIC(5y)7.97%
ROICexc(3y)8.39%
ROICexc(5y)8.35%
ROICexgc(3y)21.95%
ROICexgc(5y)21.28%
ROCE(3y)9.98%
ROCE(5y)9.86%
ROICexcg growth 3Y-3%
ROICexcg growth 5Y-4.51%
ROICexc growth 3Y-2.19%
ROICexc growth 5Y-3.47%
OM growth 3Y0.93%
OM growth 5Y0.35%
PM growth 3Y-2.65%
PM growth 5Y2.84%
GM growth 3Y0.29%
GM growth 5Y-0.02%
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF 4.16
Debt/EBITDA 2.45
Cap/Depr 69.29%
Cap/Sales 5.8%
Interest Coverage 250
Cash Conversion 83.71%
Profit Quality 135.68%
Current Ratio 1.48
Quick Ratio 1.14
Altman-Z 2.38
F-Score6
WACC9.89%
ROIC/WACC0.71
Cap/Depr(3y)98.14%
Cap/Depr(5y)87.25%
Cap/Sales(3y)7.45%
Cap/Sales(5y)6.68%
Profit Quality(3y)91.24%
Profit Quality(5y)102.62%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.4%
EPS 3Y9.37%
EPS 5Y12.09%
EPS Q2Q%-4.78%
EPS Next Y-3.27%
EPS Next 2Y-1.41%
EPS Next 3Y2.84%
EPS Next 5Y6.53%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y12.2%
Revenue growth 5Y12.75%
Sales Q2Q%-1.64%
Revenue Next Year-1.71%
Revenue Next 2Y-0.99%
Revenue Next 3Y1.38%
Revenue Next 5Y4.62%
EBIT growth 1Y-8.35%
EBIT growth 3Y13.24%
EBIT growth 5Y13.15%
EBIT Next Year21.32%
EBIT Next 3Y9.41%
EBIT Next 5Y10.2%
FCF growth 1Y100.42%
FCF growth 3Y-1.3%
FCF growth 5Y4.21%
OCF growth 1Y29.64%
OCF growth 3Y7.76%
OCF growth 5Y9.35%